Study: Omicron evades some but not all monoclonal antibodies

Several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the omicron variant now sweeping across the United States, researchers reported Jan. 19 in the journal Nature Medicine.

Newest Omicron subvariants can evade boosters, antibody therapies

Archive, monoclonal antibodies

Frontiers Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period

Omicron evades roughly twice the number of SARS-CoV-2 neutralizing antibodies than Delta

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants - Ao - 2023 - MedComm - Wiley Online Library

SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection - ScienceDirect

Omicron may not evade all monoclonal antibodies, lab study suggests, ET HealthWorld

Monoclonal antibodies

What to know about the omicron variant and subvariant BA.2 - The Washington Post

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages - ScienceDirect

Covid-19: New Omicron offshoot BA.4.6 evades protection of Evusheld antibodies, study finds